{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T21:15:32Z","timestamp":1722287732104},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2000,12]]},"DOI":"10.1007\/s11920-000-0010-x","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T21:08:27Z","timestamp":1180732107000},"page":"508-513","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacotherapies for cocaine dependence"],"prefix":"10.1007","volume":"2","author":[{"given":"Grace","family":"O\u2019Leary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10_CR1","volume-title":"Main Findings 1998","author":"National Household Survey on Drug Abuse","year":"2000","unstructured":"National Household Survey on Drug Abuse: Main Findings 1998. In Rockville: SAMHSA, Office of Applied Studies; 2000."},{"key":"10_CR2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archpsyc.1989.01810020024005","volume":"46","author":"ML Griffin","year":"1989","unstructured":"Griffin ML, Weiss RD, Mirin SM: A comparison of male and female cocaine abusers. Arch Gen Psychiatry 1989, 46:122\u2013126.","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archpsyc.1991.01810250045005","volume":"48","author":"BJ Rounsaville","year":"1991","unstructured":"Rounsaville BJ, Anton SF, Carroll K, et al.: Psychiatric diagnosis of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991, 48:43\u201351.","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/00952998609083740","volume":"12","author":"RD Weiss","year":"1986","unstructured":"Weiss RD, Mirin SM, Michael JL, et al.: Psychopathology in chronic cocaine abusers. Am J Drug Alcohol Abuse 1986, 12:17\u201329.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10_CR5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00005053-198812000-00004","volume":"176","author":"RD Weiss","year":"1988","unstructured":"Weiss RD, Mirin SM, Griffin ML, et al.: Psychopathology in cocaine abusers: Changing trends. J Nerv Ment Dis 1988, 176:719\u2013725.","journal-title":"J Nerv Ment Dis"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-4899-1648-8_2","volume-title":"Recent Developments in Alcoholism","author":"D Gorelick","year":"1992","unstructured":"Gorelick D: Alcohol and cocaine: clinical and pharmacological interactions. In Recent Developments in Alcoholism, vol 10. Edited by Galanter M. New York: Plenum; 1992, 37\u201356."},{"key":"10_CR7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0010-440X(93)90040-B","volume":"34","author":"RD Weiss","year":"1993","unstructured":"Weiss RD, Mirin SM, Griffin ML, et al.: Personality disorders in cocaine dependence. Compr Psychiatry 1993, 34:145\u2013149.","journal-title":"Compr Psychiatry"},{"key":"10_CR8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/archpsyc.56.6.493","volume":"56","author":"P Crits-Christoph","year":"1999","unstructured":"Crits-Christoph P, Siqueland L, Blaine J, et al.: Psychosocial treatments for cocaine dependence. Result of the National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry, 1999, 56:493\u2013502. This study was a multi-site, randomized clinical trial of psychosocial treatments for 487 patients with cocaine dependence. Patients were randomized to receive cognitive behavior therapy (CBT) or supportive-expressive psychotherapy (SE) plus group drug counseling (GDC), individual drug counseling (IDC) plus GDC, or GDC alone. Patients randomized to IDC and GDC attended fewer sessions than patients in other arms of the trial, but had the significantly better drug use outcome that CBT plus GDC, SE plus GDC, or GDC alone.","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1126\/science.2820058","volume":"237","author":"MC Ritz","year":"1987","unstructured":"Ritz MC, Lamb RJ, Goldberg SR, et al.: Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237:1219\u20131223.","journal-title":"Science"},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/syn.890060108","volume":"6","author":"MP Galloway","year":"1990","unstructured":"Galloway MP: Regulation of dopamine and serotonin synthesis by acute administration of cocaine. Synapse 1990, 6:63\u201372.","journal-title":"Synapse"},{"key":"10_CR11","first-page":"67","volume":"21","author":"D Taylor","year":"1978","unstructured":"Taylor D, Ho BT: Comparison of inhibition of monoamine uptake by cocaine, methylphenidate and amphetamine. Res Commun Chem Pathol Pharmacol 1978, 21:67\u201375.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10_CR12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0740-5472(95)02015-2","volume":"12","author":"A Oliveto","year":"1995","unstructured":"Oliveto A, Kosten TR, Schottenfeld R, et al.: Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. J Subst Abuse Treat 1995, 12:423\u2013428.","journal-title":"J Subst Abuse Treat"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0376-8716(92)90004-V","volume":"31","author":"AI Alterman","year":"1992","unstructured":"Alterman AI, Droba M, Antelo RE, et al.: Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend 1992, 31:19\u201329.","journal-title":"Drug Alcohol Depend"},{"key":"10_CR14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0165-1781(87)90086-2","volume":"20","author":"CA Dackis","year":"1987","unstructured":"Dackis CA, Gold MS, Sweeney DR, et al.: Single-dose bromocriptine reverses cocaine craving. Psychiatry Res 1987, 20:261\u2013264.","journal-title":"Psychiatry Res"},{"key":"10_CR15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/0091-3057(89)90478-4","volume":"33","author":"K Kumor","year":"1989","unstructured":"Kumor K, Sherer M, Jaffe J: Effects of bromocriptine pretreatment on subjective and physiological responses to IV cocaine. Pharmacol Biochem Behav 1989, 33:829\u2013837.","journal-title":"Pharmacol Biochem Behav"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/archpsyc.1992.01820110058009","volume":"49","author":"TR Kosten","year":"1992","unstructured":"Kosten TR, Morgan CM, Falcione J, et al.: Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992, 49:894\u2013898.","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/00952999108992817","volume":"17","author":"WW Weddington Jr","year":"1991","unstructured":"Weddington WW Jr, Brown BS, Haertzen CA, et al.: Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 1991, 17:137\u2013152.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10_CR18","first-page":"54","volume":"6","author":"L Handelsman","year":"1997","unstructured":"Handelsman L, Rosenblum A, Palij M, et al.: Bromocriptine for cocaine dependence. A controlled clinical trial. Am J Drug Alcohol Abuse 1997, 6:54\u201364.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0033-3182(86)72599-1","volume":"27","author":"FH Gawin","year":"1986a","unstructured":"Gawin FH: New uses of antidepressants in cocaine abuse. Psychosomatics 1986a, 27(Suppl):24\u201329.","journal-title":"Psychosomatics"},{"key":"10_CR20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00002826-198604000-00013","volume":"9","author":"FH Gawin","year":"1986b","unstructured":"Gawin FH, Byck R, Kleber HD: Desipramine augmentation of cocaine abstinence: Initial results. Clin Neuropharmacol 1986b, 9(Suppl):202\u2013204.","journal-title":"Clin Neuropharmacol"},{"key":"10_CR21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/archpsyc.1989.01810020019004","volume":"46","author":"FH Gawin","year":"1989","unstructured":"Gawin FH, Kleber HD, Byck R, et al.: Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989, 46:117\u2013121.","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1001\/jama.1988.03410170093041","volume":"260","author":"RD Weiss","year":"1988","unstructured":"Weiss RD: Relapse to cocaine abuse after initiating desipramine treatment. JAMA 1988, 260:2545\u20132546.","journal-title":"JAMA"},{"key":"10_CR23","first-page":"442","volume":"48","author":"TR Kosten","year":"1987","unstructured":"Kosten TR, Schumann B, Wright D, et al.: A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. J Clin Psychiatry 1987, 48:442\u2013444.","journal-title":"J Clin Psychiatry"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/archpsyc.1992.01820110052008","volume":"49","author":"IO Arndt","year":"1992","unstructured":"Arndt IO, Dorozynsky L, Woody GE, et al.: Desipramine treatment of cocaine dependence in methadonemaintained patients. Arch Gen Psychiatry 1992, 49:888\u2013893.","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR25","first-page":"31","volume":"52","author":"MH Pollack","year":"1991","unstructured":"Pollack MH, Rosenbaum JF: Fluoxetine treatment of cocaine abuse in heroin addicts. J Clin Psychiatry 1991, 52:31\u201333.","journal-title":"J Clin Psychiatry"},{"key":"10_CR26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00004714-199308000-00003","volume":"13","author":"SL Batki","year":"1993","unstructured":"Batki SL, Manfredi LB, Jacob P, et al.: Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine\/benzoylecgonine concentrations. J Clin Psychopharmacol 1993, 13:243\u2013250.","journal-title":"J Clin Psychopharmacol"},{"key":"10_CR27","first-page":"396","volume":"14","author":"SL Walsh","year":"1994","unstructured":"Walsh SL, Preston KL, Sullivan JT, et al.: Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 1994, 14:396\u2013407.","journal-title":"J Clin Psychopharmacol"},{"key":"10_CR28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00004714-199506000-00004","volume":"15","author":"J Grabowski","year":"1995","unstructured":"Grabowski J, Rhoades H, Elk R, et al.: Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: Two placebo-controlled double-blind trials. J Clin Psychopharmacol 1995, 15:163\u2013174.","journal-title":"J Clin Psychopharmacol"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/archpsyc.1991.01810250089015","volume":"48","author":"A Margolin","year":"1991","unstructured":"Margolin A, Kosten T, Petrakis I, et al.: Bupropion reduces cocaine abuse in methadone-maintained patients [letter]. Arch Gen Psychiatry 1991, 48:87.","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0376-8716(95)01198-6","volume":"40","author":"A Margolin","year":"1995","unstructured":"Margolin A, Kosten TR, Avants SK, et al.: A multicenter trial of bupropion for cocaine dependence in methadonemaintained patients. Drug Alcohol Depend 1995, 40:125\u2013131.","journal-title":"Drug Alcohol Depend"},{"key":"10_CR31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1176\/ajp.148.5.667","volume":"148","author":"EV Nunes","year":"1991","unstructured":"Nunes EV, Quitkin FM, Brady R, et al.: Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am J Psychiatry 1991, 148:667\u2013669.","journal-title":"Am J Psychiatry"},{"key":"10_CR32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/02791072.1991.10471612","volume":"23","author":"DM Ziedonis","year":"1991","unstructured":"Ziedonis DM, Kosten TR: Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J Psychoactive Drugs 1991, 23:417\u2013425.","journal-title":"J Psychoactive Drugs"},{"key":"10_CR33","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archpsyc.1984.01790200085011","volume":"41","author":"FH Gawin","year":"1984","unstructured":"Gawin FH, Kleber HD: Cocaine abuse treatment. Open pilot trial with desipramine and lithium carbonate. Arch Gen Psychiatry 1984, 41:903\u2013909.","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1081\/ADA-100100588","volume":"26","author":"DM McDowell","year":"2000","unstructured":"McDowell DM, Levin FR, Seracini AM, et al.: Venlafaxine treatment of cocaine abusers with depressive disorders. Am J Drug Alcohol Abuse 2000, 26:25\u201331.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10_CR35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0447.1984.tb07156.x","volume":"313","author":"RM Post","year":"1984","unstructured":"Post RM, Uhde TW, Wolff EA: Profile of clinical efficacy and side effects of carbamazepine in psychiatric illness: Relationship to blood and CSF levels of carbamazepine and its -10,11-epoxide metabolite. Acta Psychiatr Scand 1984, 313(Suppl):104\u2013120.","journal-title":"Acta Psychiatr Scand"},{"key":"10_CR36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0773.1993.tb01331.x","volume":"72","author":"NL Benowitz","year":"1993","unstructured":"Benowitz NL: Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 1993, 72:3\u201312.","journal-title":"Pharmacol Toxicol"},{"key":"10_CR37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0376-8716(95)01100-D","volume":"38","author":"HR Kranzler","year":"1995","unstructured":"Kranzler HR, Bauer LO, Hersh D, et al.: Carbamazepine treatment of cocaine dependence: A placebo-controlled trial. Drug Alcohol Depend 1995, 38:203\u2013211.","journal-title":"Drug Alcohol Depend"},{"key":"10_CR38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0376-8716(95)01165-3","volume":"39","author":"D Hersh","year":"1995","unstructured":"Hersh D, Bauer LO, Kranzler HR: Carbamazepine and cocaine-cue reactivity. Drug Alcohol Depend 1995, 39:213\u2013221.","journal-title":"Drug Alcohol Depend"},{"key":"10_CR39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0376-8716(95)01101-4","volume":"38","author":"ID Montoya","year":"1995","unstructured":"Montoya ID, Levin FR, Fudala PJ, et al.: Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Depend 1995, 38:213\u2013219.","journal-title":"Drug Alcohol Depend"},{"key":"10_CR40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0376-8716(95)01102-5","volume":"38","author":"JW Cornish","year":"1995","unstructured":"Cornish JW, Maany I, Fudala PJ, et al.: Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend 1995, 38:221\u2013227.","journal-title":"Drug Alcohol Depend"},{"key":"10_CR41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02316861","volume":"105","author":"C Muntaner","year":"1991","unstructured":"Muntaner C, Kumor KM, Nagoshi C, et al.: Effectsof nifedipine pretreatment on subjective and cardiovascular responses to intravenous cocaine in humans. Psychopharmacology (Berl) 1991, 105:37\u201341.","journal-title":"Psychopharmacology (Berl)"},{"key":"10_CR42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/02791072.1999.10471733","volume":"31","author":"R Malcolm","year":"1999","unstructured":"Malcolm R, Brady KT, Moore J, et al.: Amlodipine treatment of cocaine dependence. J Psychoactive Drugs 1999, 31:117\u2013120.","journal-title":"J Psychoactive Drugs"},{"key":"10_CR43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/00952999609001652","volume":"22","author":"RD Weiss","year":"1996","unstructured":"Weiss RD, Martinez-Raga J, Hufford C: The significance of a coexisting opioid use disorder in cocaine dependence: An empirical study. Am J Drug Alcohol Abuse 1996, 22:173\u2013184.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10_CR44","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/clpt.1983.70","volume":"33","author":"JF Towell 3d","year":"1983","unstructured":"Towell JF 3d, Cho JK, Roh BL, et al.: Disulfiram and erythrocyte aldehyde dehydrogenase inhibition. Clin Pharmacol Ther 1983, 33:517\u2013521.","journal-title":"Clin Pharmacol Ther"},{"key":"10_CR45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.1992.tb03309.x","volume":"86","author":"EN Petersen","year":"1992","unstructured":"Petersen EN: The pharmacology and toxicology of disulfiram and its metabolites. Acta Psychiatr Scand 1992, 86:7\u201313.","journal-title":"Acta Psychiatr Scand"},{"key":"10_CR46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s002040050233","volume":"69","author":"S Caroldi","year":"1995","unstructured":"Caroldi S, DeParis P: Comparative effects of two dithiocarbamates disulfiram and thiram, on adrenal catecholamine content and on plasma dopamine-b-hydroxylase activity. Arch Toxicol 1995, 69:690\u2013693.","journal-title":"Arch Toxicol"},{"key":"10_CR47","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/0024-3205(77)90448-9","volume":"20","author":"DJ Stewart","year":"1977","unstructured":"Stewart DJ, Inaba T, Tang BK, et al.: Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci 1977, 20:1557\u20131564.","journal-title":"Life Sci"},{"key":"10_CR48","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/0006-3223(94)00361-6","volume":"37","author":"FA Hameedi","year":"1995","unstructured":"Hameedi FA, Rosen MI, McCance-Katz EF, et al.: Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry 1995, 37:560\u2013563.","journal-title":"Biol Psychiatry"},{"key":"10_CR49","first-page":"675","volume":"150","author":"ST Higgins","year":"1993","unstructured":"Higgins ST, Budney AJ, Bickel WK, et al.: Disulfiram therapy in patients abusing cocaine and alcohol [letter]. Am J Psychiatry 1993, 150:675\u2013676.","journal-title":"Am J Psychiatry"},{"key":"10_CR50","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0006-3223(97)00506-4","volume":"43","author":"EF McCance-Katz","year":"1998","unstructured":"McCance-Katz EF, Kosten TR, Jatlow P: Chronic disulfiram treatment effects on intranasal cocaine administration: Initial results. Biol Psychiatry 1998, 43:540\u2013543. This paper described significant increases in heart rate, blood pressure, and anxiety in six alcohol- and cocaine-dependent individuals who received intranasal cocaine after treatment with disulfiram 250 mg\/day for 3 days. By inhibiting enzymes necessary for the metabolism of dopamine and cocaine, disulfiram may cause increases in central nervous system dopamine, leading to unpleasant symptoms such as anxiety, paranoia, and dysphoria. These symptoms and the inability to treat them with alcohol, for fear of an alcohol-disulfiram reaction, may decrease use of cocaine in subjects who use both cocaine and alcohol.","journal-title":"Biol Psychiatry"},{"key":"10_CR51","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0006-3223(99)00310-8","volume":"47","author":"TP George","year":"2000","unstructured":"George TP, Chawarski MC, Pakes J, et al.: Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry 2000, 47:1080\u20131086. Twenty opiate- and cocaine-dependent individuals treated with buprenorphine were randomized in a double-blind, placebocontrolled fashion to receive either 250 mg disulfiram or placebo each day for 12 weeks. When compared with controls, the disulfiram group had a significant increase in total time abstinent from cocaine, faster acquirement of cocaine-free urine tests, and higher rates of cocainenegative urine tests throughout a significant period of the trial.","journal-title":"Biol Psychiatry"},{"key":"10_CR52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1360-0443.2000.9522198.x","volume":"95","author":"IL Petrakis","year":"2000","unstructured":"Petrakis IL, Carroll KM, Nich C, et al.: Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000, 95:219\u2013228. In this 12-week trail, 67 opiate- and cocaine-dependent individuals receiving methadone maintenance therapy were randomized in a double-blind, placebo-controlled manner to receive either 250 mg disulfiram or placebo each day. Of the 52 subjects who completed the trial, those who received disulfiram decreased the amount and frequency of cocaine use when compared with the placebo group. Because the subjects\u2019 use of alcohol at the beginning of the study did not affect the study outcomes, disulfiram may have effects on cocaine use independent of its effects on drinking behavior.","journal-title":"Addiction"},{"key":"10_CR53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-199602000-00010","volume":"16","author":"EC Strain","year":"1996","unstructured":"Strain EC, Stitzer ML, Liebson IA, et al.: Buprenorphine versus methadone in the treatment of opioid dependence: Self-reports, urinalysis, and Addiction Severity Index. J Clin Psychopharmacol 1996, 16:58\u201367.","journal-title":"J Clin Psychopharmacol"},{"key":"10_CR54","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archpsyc.56.12.1101","volume":"56","author":"MK Romach","year":"1999","unstructured":"Romach MK, Glue P, Kampman K, et al.: Attenuation of the euphoric effects of cocaine by the dopamine D1\/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 1999, 56:1101\u20131106. Ecopipam, a dopamine-selective D1\/D5 antagonist, was given in a randomized, double-blind, placebo-controlled fashion to 11 cocaine-dependent individuals on 4 separate days during a 2-week hospitalization. Two hours after receiving placebo, 10 mg, 25 mg, or 100 mg of oral ecopipam, the subjects were given 30 mg of intravenous cocaine. Ecopipam at 100 mg was most effective for reducing euphoria and anxiety associated with cocaine use, as well as the desire to use cocaine. The 10-mg dose had no effect on the outcome measures whereas the 25-mg dose had an intermediate effect. Ecopipam was well tolerated with side effects that included headache, dyspepsia, and somnolence.","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR55","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1358\/mf.1999.21.8.794835","volume":"21","author":"XA Alvarez","year":"1999","unstructured":"Alvarez XA, Mouzo R, Pichel V, et al.: Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer\u2019s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol 1999, 21:633\u2013644.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10_CR56","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1212\/WNL.49.3.671","volume":"49","author":"MD Clark","year":"1997","unstructured":"Clark MD, Warach SJ, Pettigrew LC, et al.: A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology 1997, 49:671\u2013678.","journal-title":"Neurology"},{"key":"10_CR57","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0024-3205(94)00427-T","volume":"56","author":"GB Weiss","year":"1995","unstructured":"Weiss GB: Metabolism and actions of CDP-choline as an endogenous compount and administered exogenously as citicoline. Life Sci 1995, 56:637\u2013660.","journal-title":"Life Sci"},{"key":"10_CR58","first-page":"1","volume":"17","author":"JJ Secades","year":"1995","unstructured":"Secades JJ, Frontera G: CDP-choline: Pharmacological and clinical review. Meth Find Exp Clin Pharmacol 1995, 17(Suppl):1\u201354.","journal-title":"Meth Find Exp Clin Pharmacol"},{"key":"10_CR59","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s002130050871","volume":"142","author":"PF Renshaw","year":"1999","unstructured":"Renshaw PF, Daniels S, Lundahl LH, et al.: Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology (Berl) 1999, 142:132\u2013138. Citicoline (CDP-choline), an agent that has shown promise in the treatment of neurologic disorders in which cell membranes have been damaged, was given to 14 cocaine-dependent individuals in this 2-week, randomized, double-blind, placebo-controlled trial. Citicoline increases levels of dopamine and norepinephrine in the central nervous system. It also increases the rate at which phospholipids are integrated into cell membranes. Because of this dual action of citicoline, six subjects received 500 mg citicoline twice per day whereas eight subjects received placebo. Citicoline treatment was associated with a significant decrease in feelings of lack of control over cocaine use, a significant decrease in anxiety, and a decreased urge to use cocaine.","journal-title":"Psychopharmacology (Berl)"},{"key":"10_CR60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0376-8716(97)00158-0","volume":"49","author":"TR Kosten","year":"1998","unstructured":"Kosten TR: Pharmacotherapy of cerebral ischemia in cocaine dependence. Drug Alcohol Depend 1998, 49:133\u2013144. This paper describes a study of six cocaine-dependent subjects on an inpatient unit for cocaine detoxification who were treated with 325 mg of aspirin per day for 2 to 4 weeks. The subjects had three SPECT brain scans, one at the time of admission to the hospital, one after 2 weeks of aspirin therapy, and one at 4 weeks of aspirin therapy. A 50% improvement in cerebral blood flow to areas of deficit was seen from week 0 to week 4, with the greatest improvement seen in the first 2 weeks of aspirin treatment.","journal-title":"Drug Alcohol Depend"},{"key":"10_CR61","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1161\/01.STR.26.6.1114","volume":"26","author":"JP Konzen","year":"1995","unstructured":"Konzen JP, Levine SR, Garcia JH: Vasospasm and thrombus formation as possible mechanisms of stroke related to alkaloidal cocaine. Stroke 1995, 26:1114\u20131118.","journal-title":"Stroke"},{"key":"10_CR62","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","volume":"72","author":"GJ Roth","year":"1975","unstructured":"Roth GJ, Stanford N, Majerus PW: Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975, 72:3073\u20133076.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR63","unstructured":"Kosten TR, Seibyl J, Rinder H, et al.: Reducing cocaine-related cerebral perfusion deficits with anti-platelet agents: SPECT analyses using SPM. Proceedings of 62nd Annual Scientific Meeting. Puerto Rico: College on Problems of Drug Dependence; July 17\u2013July 22, 2000. Sixty-nine, active cocaine users were treated daily with 325 mg aspirin. SPECT scanning demonstrated improved cerebral blood flow and improved neuropsychologic testing after receiving aspirin therapy. Aspirin may be a useful agent in treating cocaine-related cerebral damage in cocaine dependent individuals."},{"key":"10_CR64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0162-3109(92)90023-6","volume":"23","author":"O Bagasra","year":"1992","unstructured":"Bagasra O, Forman LJ, Howeedy A, et al.: A potential vaccine for cocaine abuse prophylaxis. Immunopharmacology 1992, 23:173\u2013179.","journal-title":"Immunopharmacology"},{"key":"10_CR65","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/382568b0","volume":"382","author":"S Nadis","year":"1996","unstructured":"Nadis S: Drugs institute gives grant for cocaine vaccine. Nature 1996, 382:568.","journal-title":"Nature"},{"key":"10_CR66","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nm1096-1129","volume":"2","author":"BS Fox","year":"1996","unstructured":"Fox BS, Kantak KM, Edwards MA, et al.: Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996, 2:1129\u20131132.","journal-title":"Nat Med"},{"key":"10_CR67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0376-8716(97)00121-X","volume":"48","author":"BS Fox","year":"1997","unstructured":"Fox BS: Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend 1997, 48:153\u2013158.2000, 87.","journal-title":"Drug Alcohol Depend"},{"key":"10_CR68","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1073\/pnas.97.11.6202","volume":"97","author":"MR Carrera","year":"2000","unstructured":"Carrera MR, Ashley JA, Zhou B, et al.: Cocaine vaccines: Antibody protection against relapse in a rat model. Proc Natl Acad Sci U S A 2000, 97:6202\u20136206. In this study, rats who were trained to self-administer cocaine were treated with a cocaine vaccine. Vaccinated rats did not reinstate cocaine self-administration after receiving a single priming dose of cocaine, whereas the nonvaccinated rats returned to self-administration of cocaine after the same priming dose. When the priming dose of cocaine was doubled and then tripled, the majority of vaccinated rats did not reinstate cocaine use whereas all nonvaccinated rats did. Passive immunization with monoclonal IgG GNC92H2, a cocaine antagonist, fully prevented reinstatement of cocaine self-administration in both vaccinated and nonvaccinated rats.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-000-0010-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-000-0010-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-000-0010-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:38:47Z","timestamp":1559435927000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-000-0010-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s11920-000-0010-x","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}